ENDRA Life Sciences (NDRA) Tops Q4 EPS by 1c

ENDRA Life Sciences (NASDAQ: NDRA) reported Q4 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08).

Cash and cash equivalents were $9.5 million as of December 31, 2021.

For earnings history and earnings-related data on ENDRA Life Sciences (NDRA) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• General Mills beats estimates as cost savings offset volumes
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print